HER2-positive breast cancer Cardiotoxicity Breast cancer Cardiotoxicity
Conditions
Interventions
Aim 1: To determine the temporal changes of biomarkers, cardiac function, mitochondrial function, oxidative stress and cell viability in isolated PBMCs in breast cancer patients receiving sequential d
Control,Melatonin,Ranolazine
Sponsors
The National Science and Technology Development Agency Thailand
Eligibility
Sex/Gender
Female
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: - Newly diagnosed breast cancer, required breast surgery and chemotherapy - Over-expressed HER2 in breast cancer
Exclusion criteria
Exclusion criteria: - HER2-negative breast cancer - Metastatic breast cancer at diagnosis, except lymph node and bone metastasis - History of other cancer(s) - Prior chemotherapy - LVEF below 53% at baseline or below 50% before trastuzumab treatment - End-stage disease (i.e., renal, liver) or life expectancy less than 1 year - Pregnancy - Allergy to medications used in the study - Corrected QT interval more than 500 ms - Informed or treatment refusal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Global longitudinal strain 12 months Echocardiography | — |
Secondary
| Measure | Time frame |
|---|---|
| Mitochondrial respiration in PBMCs 12 months Seahorse extracellular flux analyzer,Oxidative stress in PBMCs 12 months MitoSOX/MitoTracker staining ,Cell viability in PBMCs 12 months Propidium iodide flow cytometry | — |
Countries
Thailand
Contacts
Public ContactSiriluck Gunaparn
Faculty of Medicine, Chiang Mai University
Outcome results
None listed